emtricitabine / tenofovir alafenamide Generic Marketing Authorization Application for HIV submitted to EMA

A new marketing authorization application for a generic emtricitabine/tenofovir alafenamide is present in the list of application for new human medicines under evaluation by the CHMP.

EMA evaluation process started on 20 June 2024.

Considering standard assessment process, approval might come by 2Q/2025.

Source: Applications for new human medicines under evaluation by the CHMP